First-line treatment options for metastatic non-squamous non-small-cell lung cancer (NSCLC) have expanded in the past couple of decades. They have grown from platinum-doublet chemotherapy, to include targeted therapies and combination therapy with monoclonal antibodies targeting programmed death 1 (PD-1) or programmed death ligand 1 (PD-L1).1Our collective understanding of the molecular mechanisms behind NSCLC has likewise expanded – ...
Empowering personalised medicine in NSCLC – insights from the IMpower150 subgroup analysis
9 Dec 2021
Sponsored by Roche